Emerging Treatment Approaches and Multidisciplinary Management of Unresectable Stage III Non-Small Cell Lung Cancer - Episode 10
Expert Insights on the LAURA Trial: Osimertinib After CRT in Unresectable Stage III EGFRm NSCLC as a New Standard of Care
The discussion focuses on the LAURA trial, which demonstrated that osimertinib significantly improved progression-free survival in patients with EGFR-mutated (EGFRm) locally advanced non–small cell lung cancer (NSCLC) after chemoradiotherapy (CRT), establishing it as a new standard of care with manageable safety concerns.
Video Player is loading.
Video content above is prompted by the following:
- Please provide some background on the LAURA trial evaluating osimertinib after definitive CRT in unresectable stage III EGFRm NSCLC
